PYRGF vs. CRDF, IMMP, TSVT, FHTX, AMRN, AARD, INZY, TIL, LFCR, and DBVT
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Cardiff Oncology (CRDF), Immutep (IMMP), 2seventy bio (TSVT), Foghorn Therapeutics (FHTX), Amarin (AMRN), Aardvark Therapeutics (AARD), Inozyme Pharma (INZY), Instil Bio (TIL), Lifecore Biomedical (LFCR), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.
PyroGenesis Canada vs. Its Competitors
PyroGenesis Canada (NASDAQ:PYRGF) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
PyroGenesis Canada has a net margin of -115.14% compared to Cardiff Oncology's net margin of -6,238.17%. PyroGenesis Canada's return on equity of 0.00% beat Cardiff Oncology's return on equity.
In the previous week, Cardiff Oncology had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for Cardiff Oncology and 3 mentions for PyroGenesis Canada. Cardiff Oncology's average media sentiment score of 1.71 beat PyroGenesis Canada's score of -0.50 indicating that Cardiff Oncology is being referred to more favorably in the news media.
0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cardiff Oncology has a consensus target price of $12.00, indicating a potential upside of 216.62%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than PyroGenesis Canada.
Cardiff Oncology received 43 more outperform votes than PyroGenesis Canada when rated by MarketBeat users.
PyroGenesis Canada has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
PyroGenesis Canada has higher revenue and earnings than Cardiff Oncology. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Cardiff Oncology beats PyroGenesis Canada on 11 of the 17 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
This page (NASDAQ:PYRGF) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy PYRGF Stock Free PYRGF Stock Alerts